A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B; HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms Alliance
- Sponsors Gilead Sciences
- 10 Apr 2019 Planned End Date changed from 1 Aug 2023 to 1 Mar 2023.
- 20 Mar 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Mar 2021.
- 15 Jun 2018 Status changed from not yet recruiting to recruiting.